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Background: Combined pulmonary fibrosis and emphysema (CPFE) is an umbrella term encompassing upper lobe
emphysema and lower lobe pulmonary fibrosis with pathogenesis elusive. The aim of our study was to investigate
the incidence of autoimmune markers in patients with CPFE.
Methods: In this multicenter study we retrospectively evaluated records from patients with CPFE (n=40) and IPF
(n=60) without emphysema. Baseline demographic characteristics, high-resolution computed tomography (HRCT),
spirometry, histopathological, treatment, serum immunologic and survival data were investigated. B cell presence was
estimated with CD20 immunostaining in representative lung biopsy samples from CPFE patients and control subjects.
Results: A statistically significant increased number of CPFE patients with elevated serum ANA with or without positive
p-ANCA titers compared to patients with IPF without emphysema was observed. Patients with CPFE and positive
autoimmune markers exhibited improved survival compared to patients with a negative autoimmune profile. A
massive infiltration of clusters of CD20+ B cells forming lymphoid follicles within the fibrotic lung in CPFE patients with
positive serum immunologic profile compared to patients with negative profile, was noted and positively correlated
with improved survival.
Conclusions: A significant proportion of patients with CPFE may present with underlying auto-immune disorders that
may reside insidiously and be associated with favorable prognosis. Early identification of these patients using a panel of
auto-antibodies may lead to more targeted and effective therapeutic applications.Background
The combination of pulmonary fibrosis and emphysema
(CPFE) is a recently defined syndrome, encompassing a
distinct radiologic, revealing both upper lobe emphy-
sema and lower lobe fibrosis in high resolution com-
puted tomography (HRCT) of the chest, as well as lung
function profile, with apparently preserved lung volumes
contrasting with disproportionally impaired gas ex-
change, as assessed by reduced diffusing lung capacity
for carbon monoxide (DLco) [1-3]. It is associated with
severe exercise hypoxemia and increased prevalence of* Correspondence: bouros@med.duth.gr
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distribution, and reproduction in any mediumpulmonary hypertension, two major determinants of dis-
mal prognosis, with a 1-year survival of only 60% if
present and a median survival of 6.1 years if absent [4].
The syndrome of CPFE has been recently individualized
within the spectrum of smoking-induced chronic lung
diseases. In addition CPFE has been recently described
in the context of connective tissue diseases [5] implicat-
ing autoimmunity in the pathogenesis of both pulmon-
ary fibrosis and emphysema.
In the past, despite seminal reports pointing to an as-
sociation between immune deregulation and paradigms
of chronic lung injury [6], the role of autoimmunity in
the pathogenetic cascade of both idiopathic pulmonary
fibrosis (IPF) and chronic obstructive pulmonary disease
(COPD) has been severely overlooked mainly due to thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and COPD and the disappointing results of the current
immunosuppressive and immunomodulatory agents in
patients with IPF [7-10]. Nevertheless, interest in the
role of autoimmunity in the pathophysiology of both IPF
and COPD was revived by recent studies reporting
highly activated and proliferative CD4+ cells [11] and
global numerical and functional impairment of T regula-
tory cells [12], as well as presence of circulating auto-
antibodies against nuclear and cytoplasmic antigens in
both IPF and COPD patients [13,14]. Moreover, a close
linkage between pulmonary fibrosis and microscopic
polyangiitis (MPA), a type of systemic necrotizing small
vasculitis characterized by both pulmonary and renal in-
volvement and associated with circulating antineutrophil
cytoplasm antibodies (ANCAs) against myeloperoxidase
(MPO), has been recently identified in both clinical [15]
and experimental setting [16]. The latter implies that an
ongoing autoimmune process through recognition of
self-antigens may take place in a subgroup of patients
initially presented with a diagnosis of IPF. In line with
this notion, a considerable number of patients seminally
set under the diagnostic umbrella of idiopathic intersti-
tial pneumonia (IIP), either non-specific (NSIP) or IPF
meet the case definition of undifferentiated connective
tissue disorder and may evolve through disease course
into a specific connective tissue disorder with compat-
ible clinical and serum immunologic profile [17,18].
Based on the above evidence, a significant proportion of
both IPF and COPD patients present with a flare of auto-
immunity that may reside occultly under the diagnostic
“cover” of interstitial lung fibrosis and/or emphysema.
Since CPFE presents with pathogenesis still elusive and
controversial and it is debatable whether it represents a
distinct syndrome facilitated by a common pathogenetic
cascade leading to both fibrosis and emphysema in suscep-
tible individuals after cigarette smoke exposure or it is just
a phenotype of IPF with coincidental emphysema, we
sought to determine the autoimmunity profile, using a
panel of clinical, serum and histopathological markers, in a
large cohort of patients with CPFE and correlate our find-
ings with distinct survival patterns. Additionally our find-
ings were compared to those observed in a cohort of
patients with IPF without emphysema used as control
group. In view of the current disappointing survival data
arising from large prospective placebo-controlled clinical
trials [19,20], identification of a subgroup of patients with
CPFE with an autoimmunity background that could benefit
from immunomodulatory treatment is of vital importance.
Methods
Study design
This multicentre study enrolled consecutive patients meet-
ing the criteria for CPFE, as described by Cottin et al. [1]and patients with IPF according to the new ATS/
ERS/JRS/ALAT 2011 criteria diagnosed in three differ-
ent hospitals, (University Hospital of Alexandroupolis,
General Hospital of Kavala and General Hospital of
Serres, Greece), during the period of time between
September 2004 and August 2010. The latter group
served as control. Disease diagnosis was based on a
multidisciplinary approach (chest physician, radiologist
and pathologist). Clinical and serological data for cases
included in the study were collected and analyzed on a
retrospective basis. Patients were followed-up by August
2012 where the last data entry (clinical, serological, sur-
vival) in our retrospective analysis occurred. According to
Greek legislation informed consent is not needed for retro-
spective analyses of data corresponding to current practice.
This study was approved by Local Ethics Committee
and the institutional review board of the University
Hospital of Alexandroupolis, Democritus University of
Thrace (579-03-2012).
Serum immunologic profile
All patients (n = 100) enrolled in the study underwent a
complete clinical and serum rheumatologic review based
on the following criteria: based on the following criteria:
1) American College of Rheumatology (ACR) 1987 re-
vised criteria for the classification of rheumatoid arthritis
(RA) [21]; 2) the preliminary ACR criteria for systemic
sclerosis (SSc) [22]; 3) the criteria proposed by Kahn
et al. for mixed CTD [23]; 4) the American–European
Consensus Group criteria for Sjogren’s syndrome [24];
and 5) the criteria for polymyositis and dermatomyositis
described by Troyanov et al. [25]. Serum immunologic
included the following: 1) antinuclear antibodies (ANA)
2) anti-double strand (anti-ds) DNA antibodies 3) anti-
extractable nuclear antigens (ENA) panel including anti-
scl70, anti-Ro (SSA), anti-La (SSB), anti-Sm, anti-RNP,
4) rheumatoid factor and anti-CCPs, 5) myositis panel in-
cluding anti-Jo1 antibodies 6) complement 3 and 4 (C3,4)
levels 7) antineutrophil cytoplasm antibodies (ANCAs)
against myeloperoxidase (MPO) and proteinase-3 (PR-3).
Assessment of the above panel of immunologic markers
was performed at the following serial time points: 1) At
time of diagnosis as a part of routine work-up in order to
exclude collagen vascular diseases as a cause of lung fibro-
sis, and 2) At regular follow-up every 6 months or earlier
than 6 months if clinical signs compatible with auto-
immune disease (arthralgia, muscle weakness, dysphagia,
Raynaud’s phenomenon, photosensitivity) or disease ex-
acerbation (dyspnea deterioration, hemoptysis, hematuria)
emerged.
HRCT evaluation
All patients were subjected to HRCT of the thorax to set
the diagnosis of CPFE and IPF. One mm thick- HRCT
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intervals with a helical CT scanner (General Electric
Prospeed Series). HRCT studies at the time of disease
diagnosis were evaluated independently by 2 radiologists
who were blinded to immunology and histopathology pro-
file but were aware that the patients had CPFE syndrome.
Discrepancies were resolved by consensus. HRCT studies
were evaluated at five predetermined levels using a modifi-
cation of a semiquantitative HRCT scoring system previ-
ously described [26]. HRCT scans were evaluated for the
presence and extent of emphysema and the total extent of
interstitial lung disease including the presence of reticular
pattern, ground glass pattern and honeycombing. The
above mentioned HRCT findings were analyzed and evalu-
ated according to the Fleischner glossary of terms [27].
HRCT images were scored at five predetermined levels: 1)
origin of great vessels; 2) main carina; 3) pulmonary ven-
ous confluence; 4) halfway between the third and fifth sec-
tion; 5) immediately above the right hemi-diaphragm.
a) Extent of emphysema
The total extent of emphysema was estimated to the
nearest five percent in each of the five sections, with
global extent of emphysema on HRCT computed as
the mean of the scores. To establish the diagnosis of
CPFE on HRCT a global extent of emphysema
higher than 5% was set as threshold.
b) Total extent of interstitial lung disease
The total extent of interstitial lung disease was
estimated to the nearest five percent in each of the
five sections, with global extent of disease on HRCT
computed as the mean of the scores.
Histopathology evaluation
Based on ATS/ERS/JRS/ALAT 2011 criteria [28] for IPF
diagnosis video-assisted thoracoscopic surgery (VATS)
procedure was performed and biopsy samples from two
different lobes were obtained in selective number of cases
in order to establish a more rigid diagnosis of IPF and to
exclude other patterns of IIPs. Definite usual interstitial
pneumonia (UIP) pattern was based on the presence of
the following 4 criteria: 1) evidence of marked fibrosis,
architectural distortion and honeycombing in a predomin-
antly subpleural distribution, 2) presence of patchy in-
volvement of lung parenchyma by fibrosis, 3) presence of
fibroblastic foci, 4) absence of features against a diagnosis
of UIP including hyaline membranes, organizing pneumo-
nia, granulomas, predominant airway centered changes
and marked interstitial inflammatory cell infiltrates away
from honeycombing. Probable UIP pattern was defined
by the presence of criteria numbers 1 and 4 and the
absence of criteria numbers either 2 or 3, but not both.
On the other hand NSIP histopathological diagnosis
was defined as the presence of marked interstitialchronic inflammation, and/or interstitial fibrosis lack-
ing the temporal heterogeneity pattern and the patchy
features of UIP and the absence of fibroblastic foci [29].
Tissue microarrays
Two tissue microarray blocks comprising of a total of 58
lung tissue samples including 15 lung fibrosis biopsy sam-
ples of different histopathologic patterns derived from pa-
tients with CPFE, 28 lung samples from patients with IPF
and 15 control tissues extracted from the normal part of
the lung removed for benign lesions, was constructed as
previously reported [30]. Briefly, tissue cylinders of 2.0
mm diameter were punched from selected areas of each
“donor” block by utilizing a thin-wall stainless tube from a
precision instrument (TMA-100, Chemicon, USA) and
were transferred by a solid stainless stylet into defined
array coordinates in a 45 * 20 mm new recipient paraffin
block. Each tissue element in the array was 2.0 mm in
diameter and spacing between two adjacent elements was
0.1 mm. After the tissue microarray construction 3 μm
sections for immunohistochemical analysis were cut from
the “donor” blocks and were transferred to glass slides
using an adhesive-coated tap sectioning system.
Immunohistochemistry and semi-quantitative image
analysis
Immunohistochemistry (IHC) was performed by using spe-
cific monoclonal antibody for CD20 (mouse anti-human,
DAKO), as previously reported [31]. The number of CD20
positive cells in 5 fields per case was counted by two inde-
pendent pathologists - observers using the high-resolution
DUET, BioView scanning system for IHC morphology and
immunocytochemistry applications, at ×100 magnification.
All cell counts were expressed as cells/mm2.
Statistical analysis
Statistical analysis was carried out using SPSS 14.0 software
and Origin pro 8. Results are expressed as mean ± SD, or
median (range), unless otherwise indicated. Pearson’s chi-
square was used to compare frequencies of ANA and
ANCA positivity among two studied populations (CPFE
and IPF). Independent t-test was used to compare sero-
logical, pulmonary functional parameters between patients
with CPFE and IPF, as well as CD20 positive cells/mm2
between CPFE and control lung samples. Spearman’s cor-
relation was performed to find relationship between CD20
positive cells/mm2 and median survival in patients with




Baseline characteristics of patients enrolled in the study
are demonstrated in Table 1. In total, 40 consecutive







Age (yrs) 56 (31–74) 66 (44 – 78)
Current smokers 2 0
Ex-smokers 38 60







FEV1 %predicted 68,6 ± 19 67,8 ± 9,1
FVC %predicted 70,6 ± 21* 62,8 ± 11,4
FEV1/FVC 77,6 ±11,2 83,2 ±10,1
TLC %predicted 69,7 ± 17,9* 57,1 ± 9,1
DLCO %predicted 34,8 ±15* 44,1 ±7,2
MMEF25/75%predicted 69,3 ±35* 79,8 ±19
6MWD (m) 330 ± 168* 402 ± 112
sPAP (by echocardiography) mmHg 37,3 ± 14,5* 32,1 ± 10,9
Data are presented as median (range), No (total) or mean ± SD, unless stated
otherwise. *p < 0.05 Abbreviations: 6MWD: 6-minure walking distance,
DLCO: Diffusing Capacity for carbon monoxide, FVC: Forced vital capacity,
MMEF: maximum midexepiratory flow, sPAP: systolic pulmonary artery
pressure, TLC: Total Lung Capacity. Table 2 Clinical, functional, radiological and
histopathological characteristics of CPFE patients







Total Number 7 10 23
FEV1%pred 69,2 ± 17,1 67,8 ± 14,3 68,4 ± 18,7
FVC%pred 72,87 ± 26,6 68,96 ± 22,9 69,54 ± 21,6
DLCO%pred 35,95 ± 12,3 35,79 ± 10,7 33,9 ± 10,4
Histopathology pattern UIP UIP UIP
CD20 + cells/mm2 51.6 ± 6.9* 49.6 ± 7.1* 6.2 ± 3.6
Survival (median-range)
months
51 (12 – 96)* 38 (16 – 61)
Radiology pattern UIP UIP UIP
sPAP 36,9 ± 13,1 38,2 ± 12,8 37,1 ± 11,5
Hemoptysis 7 0 0
Hematuria 7 0 0
Arthralgias 0 3 0
Raynaud’s phenomenon 0 4 0
Dysphagia 0 1 0
Abbreviations: ANA: anti-nuclear antibodies, ANCA: antineutrophil cytoplasm
antibodies (ANCAs), DLCO: Diffusing capacity of lung for carbon monoxide, FVC:
Forced Vital Capacity, sPAP: systolic pulmonary artery pressure, UIP: Usual
Interstitial Pneumonia. *p < 0.05.
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spectively identified from the archive records of three dif-
ferent hospitals, during the period of time between
September 2004 and August 2010. Three patients with
CPFE diagnosed with MPA based on clinical evidence
(hemoptysis, hematuria), serum immunologic profile and
renal biopsy showing pauci-immune necrotizing glomer-
ulonephritis, were treated with pulses of methyprednisolone
(1gr for 3 consecutive days) and cyclophosphamide (1gr for
one day) and then, as maintenance treatment, with oral
cyclophosphamide (60 mgr/day) and high doses of oral
prednisolone (60 mg/day) that were gradually tapered, for a
total period of 7 months (n = 3), as previously described
[31]. One patient died due to respiratory and renal failure.
The remaining 4 cases with CPFE presenting with positive
p-ANCA and asymptomatic microscopic hematuria, with
normal renal function and mild gas exchange impairment,
evidence suggesting but not establishing the diagnosis of
MPA, were switched from pirfenidone treatment to a more
anti-inflammatory therapeutic regimen comprising of low
doses of prednisolone (20 mgr/day), azathioprine (2 mg/kr/
day) and high doses of NAC (1800 mgr/day).Regarding pulmonary functional profile at the time of
disease diagnosis, CPFE patients enrolled in our study
exhibited a mild restrictive pattern with relatively pre-
served lung volumes and disproportionally impaired gas
exchange and exercise capacity as indicated by DLCO
and 6-minute walking distance (6MWD) values (Table 1).
Compared to patients with IPF, patients with CPFE dem-
onstrated significantly higher FVC%pred and TLC%pred
and lower DLCO, MMEF25/75%pred and 6MWD values
(Table 1). Finally, patients with CPFE presented with a
statistically significant elevated levels of systolic pulmon-
ary artery pressure (sPAP) levels (37.3 ± 14.5 mmHg)
compared to IPF patients (32.1 ± 10.9 mmHg) (p < 0.05),
as assessed by cardiac ultrasonography (Table 2).
HRCT findings showed that the mean global extent
of emphysema was 15.7% (range: 5%-56%) and the
mean global extent of interstitial lung disease was
42.2% (range: 6%-80%).
Serum immunologic profile
All patients enrolled in the study were subjected to a
complete serum immunologic profile. Strikingly there
was a statistically significant increased number of CPFE
patients presenting with elevated (>1/160) serum titers
of ANA (n = 17/40, 42.5%) compared to patients with
IPF (n = 16/60, 26.6%), (p < 0.05) (Table 3). Among these
patients 15/17 (88%) exhibited positive ANA profile at
the time of CPFE diagnosis, therefore were naïve of
Table 3 Serum immunologic profile and clinical






Total number 40 60
ANA 17 (42.5)* 16 (26.7)
Anti-ds DNA 0 2 (3.3)
Anti-Ro (SSa) 0 0
Anti-La (SSb) 0 0
p-ANCA (MPO) 7 (17.5)* 0
c-ANCA 0 0
RF 3 (7.5) 6 (10)
Anti-CCPs 2 (5) 4 (6.6)
Anti-scl 70 1 (2.5) 2 (3.3)
Renal biopsy consistent of MPA 3 (7.5) NA
Arthralgia 3 (7.5) 6 (10)
Morning Stiffness 2 (5) 6 (10)
Raynaud’s phenomenon 4 (10) 2 (3.3)
Dysphagia 1 (3) 2 (3.3)
Hemoptysis 2 (5) 0
Hematuria 7 (17.5)* 0
Abbreviations: ANA: anti-nuclear antibodies, ANCA: antineutrophil cytoplasm
antibodies (ANCAs), anti-CCPs: anti cyclic citrullinated peptide antibodies, anti-
ds DNA: anti-double strand DNA antibodies, anti-scl 70: anti-topoisomerase I
antibodies, IPF: Idiopathic Pulmonary Fibrosis, MPA: Microscopic Polyangiitis,
MPO: myeloperoxidase, RF: rheumatoid factor, *p < 0.05.
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serum titers became positive after a mean period of 12
months following disease diagnosis. With regards to IPF
subjects, 9/16 (56.2%) reported positive ANA profile at
the time of diagnosis whereas the remaining 7/16
(43.8%) became positive after a mean follow-up period
of 18 months. Furthermore, one of the most intriguing
findings of our study was the identification of a higher
proportion of CPFE ANA+ patients that also exhibited
positive ANCAs (n = 7/40, 17.5%) against MPO compared
to IPF patients without emphysema (n = 0) (p < 0.05).
Presence of autoantibodies was estimated by both qualita-
tive (immunofluorescence) and quantitative (ELISA, mean
levels = 15,6 elisa units –EU, normal range <9.0 EU)
methods (Table 2). In 6 out of 7 patients ANA profile was
positive and p-ANCA profile was negative at the time of
CPFE diagnosis and became positive after several months
(mean period of delay = 20 months) during either disease
exacerbation (respiratory and renal failure) (n = 2) or in
the setting of routine follow-up (n = 4). In one patient both
ANA and p-ANCA concentrations were found elevated at
the time when pulmonary and renal involvement were di-
agnosed. In 3 out of 7 CPFE patients diagnosis of MPA
was firmly established by renal biopsy showing pauci-immune necrotizing glomerulonephritis while microscopic
urine analysis revealed red blood cell renal casts. The lat-
ter group of patients exhibited the most aggressive clin-
ical course comprising of respiratory and renal failure
derivative of diffuse alveolar hemorrhage and necrotiz-
ing renal vasculitis. The remaining 4 CPFE patients with
positive ANA and p-ANCA profile were characterized
by an asymptomatic microscopic hematuria, with nor-
mal renal function and mild gas exchange impairment
(Table 4).
There were no differences between the three groups of
CPFE patients based on their immunologic profile (ANA+
ANCA+, ANA + ANCA-, ANA-ANCA-) with regards
to baseline functional (FEV1, FVC, DLCO, sPAP) and
radiological (HRCT pattern) parameters (Table 3).
Nevertheless, Kaplan Meier analysis revealed a statisti-
cally significant improved survival of patients with CPFE
and positive ANA profile compared to those with negative
ANA titers (median survival 51 months-range 12–96
months vs. 38 months-range 16–61 months, p = 0.052,
respectively) (Figure 1a). There were no survival differ-
ences in patients with IPF with and without positive im-
munologic profile (data not shown), while renal function
and serologic profile returned to normal levels.
Three CPFE and 6 IPF patients with symptoms of
morning stiffness and mild arthralgia exhibited margin-
ally positive rheumatoid factor (RF) levels (>20) while
one from the CPFE and two from the IPF group of pa-
tients presented with positive ENA panel as assessed by
elevated circulating antibodies against topoisomerase
(anti-scl70) indicative of systemic sclerosis one and two
years, respectively, after the initial diagnosis of CPFE and
IPF. Finally all patients exhibited negative myositis panel.
Histopathology profile
Evaluation of the histopathology profile was performed
by two independent pathologists in tissue microarray
blocks derived from lung biopsy samples of 15 patients
with CPFE, 28 patients with IPF and 15 controls. A pat-
tern of definite UIP was revealed in 10 CPFE and 18 IPF
cases and a probable UIP pattern in 5 CPFE and 10 IPF
cases. Based on evidence arising from the investigation of
the serum immunologic profile, we performed immuno-
histochemical analysis using CD20 antibody. The number
of CD20 positive cells/mm2 was significantly higher in
CPFE ANA+ (n = 7) (49.6 ± 7.1) and IPF ANA+ (n = 9)
(47,1 ± 6.4) compared to CPFE ANA- (n = 8) (6.2 ± 3.6),
IPF ANA- (n = 19) (5.9 ± 1.6) and control lung samples
(3.2 ± 1.1) (p < 0.05) (Table 3) . There was no difference in
the number of CD20+ cells between CPFE ANA+ and IPF
ANA+ patients. Further subgroup analysis revealed that
CPFE ANCA+ patients with available lung biopsy samples
(n = 5) also exhibited statistically significant increased
CD20+ cells infiltration (51.6 ± 6.9) compared to CPFE
Table 4 Clinical, functional, survival and baseline data of patients with CPFE and ANA + ANCA + immunologic profile
with and without positive renal biopsy for MPA
Variable ANA + ANCA +with positive renal biopsy for MPA ANA+ANCA+without positive renal biopsy for MPA
Patients (n) 3 4
Renal function Renal failure normal
Hematuria (n) 3 4
Hemoptysis (n) 2 0
Gas exchange impairment Respiratory failure Mild
Treatment Pulses of methyprednisolone (1gr for 3 consecutive days)
and cyclophosphamide (1gr for one day) plus oral
cyclophosphamide (60 mgr/day) and oral prednisolone
(60 mg/day) for 7 months
Azathioprine (2mg/kgr/day), prednisolone (20mgr/day),
NAC (1800mgr/day) for 12 months
Death 1 0
FVC%pred. before Rx (∫) 60,5 ± 18,8 76,2 ± 24,5
FVC%pred. after Rx (§) 57,8 ± 17,1 70,3 ± 21,8
DLCO%pred. before Rx (∫) 29,5 ± 9,8 37,3 ±11,2
DLCO%pred. after Rx (§) 26,5 ± 10,1 35,9 ± 10,9
Abbreviations: ANA: anti-nuclear antibodies, ANCA: antineutrophil cytoplasm antibodies (ANCAs), DLCO: Diffusing capacity of lung for carbon monoxide,
FVC: Forced Vital Capacity, MPA: Microscopic polyangiitis, NAC: N-acetylcysteine, Rx: Treatment. *p < 0.05.
∫ Pulmonary function tests 3 months before treatment initiation.
§ Pulmonary function tests after treatment initiation (7 and 12 months).
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extend our previous observation that presence of positive
autoimmune profile may be a positive prognosticator we
performed Spearman’s correlation and clearly demon-
strated an almost linear positive association between the
number of CD20+ cells/mm2 and median survival in pa-
tients with CPFE (Figure 1b). There were no similar corre-
lations in patients with IPF (data not shown).
Finally and most intriguingly, as depicted in Figure 2,
CD20+ B cells forming lymphoid follicles were found
within the fibrotic interstitium in areas adjacent toFigure 1 Kaplan Meier survival and spearman’s correlation analysis in
profile. a. Kaplan-Meier survival curve revealed a marginal statistically signi
ANA profile (median survival of 51 months, range 12 – 96 months) compar
16 – 61 months) b. Spearman’s correlation analysis revealed an almost line
median survival of patients with CPFE.fibroblastic foci in both CPFE ANA+ (A, B) and CPFE
ANCA+ (C, D) lung samples whereas CD20+ cells were
almost absent in CPFE ANA-ANCA- (E, F) as well as in
control lung samples (G, H), supporting the presence of
auto-antibody producing cells. There was no difference in
CD20 + cells/mm2 between CPFE ANA+ (49.6 ± 7.1) and
CPFE ANCA+ (51.6 ± 6.9) patients.
Discussion
This is the first study in the literature investigating on a
retrospective basis the immunologic profile of a relativelypatients with CPFE with positive and negative immunologic
ficant improved survival (p = 0.052) of patients with CPFE and positive
ed to those with negative immunologic profile (38 months, range
ar positive association between the number of CD20+ cells/mm2 and
Figure 2 Presence of CD20+ B cells within the fibrotic interstitium in patients with CPFE. Representative immunohistochemistry with a CD20
antibody on lung paraffin sections from patients with CPFE with a UIP histopathologic pattern and controls. As illustrated clusters of CD20+ B cells
forming lymphoid follicles were found within the fibrotic interstitium in areas adjacent to fibroblastic foci in CPFE patients with ANA+ profile (a, b) as
well as CPFE patients with ANCA + profile (c, c), whereas CD20+ cells were almost absent in biopsy samples from patients with CPFE and negative ANCA
and ANA profile (e, f), as well as in control lung samples (g, h). Original magnification : ×200 (a, c, e and g), × 400 (b, d, f and h).
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that observed in patients with IPF without emphysema,
using a complete panel of clinical, serum and histopatho-
logic markers. Our main findings are the following: 1) An
increased number of CPFE patients with positive ANA
profile (17/40, 42.5%) compared to patients with IPFwithout emphysema (16/60, 26.6%) (p < 0.05). 2) An in-
creased number of CPFE patients with elevated serum p-
ANCA titers (7/40, 17.5%) compared to none with IPF
without emphysema (p < 0.05). The latter finding was ac-
companied by an increased prevalence of MPA (3 out of 7
patients with positive p-ANCA profile) based on renal
Tzouvelekis et al. BMC Pulmonary Medicine 2013, 13:31 Page 8 of 11
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nephritis coupled with diffuse alveolar hemorrhage while
in the remaining 4 patients immunological (positive p-
ANCA titers) clinical (mild dyspnea on exertion) and sero-
logical (microscopic hematuria with normal renal function
and 24-hour urine protein concentrations) findings were
suggestive of an occult autoimmune disorder compatible
with systemic vasculitis namely MPA. 3) A statistically
significant improved survival of patients with CPFE and
positive autoimmune profile compared to those with
negative one suggesting that presence of autoimmunity
may be associated with favorable prognosis. 4) Massive
infiltration of clusters of CD20+ cells forming lymphoid
follicles immediately adjacent to areas of fibroblastic foci
in lung biopsy samples from CPFE patients with positive
serum immunologic profile (ANCA+ and/or ANA+)
compared to patients with negative profile, suggesting
the presence of antibody producing B cells within the
injured lung. 5) A linear positive correlation of CD20+
cells with median survival in patients with CPFE indicat-
ing this histopathologic marker as a potentially reliable
disease prognosticator.
CPFE represents a distinct underecognised entity semin-
ally defined by Cottin et al. [1-5] as a syndrome character-
ized by frequent paraseptal emphysema with upper zone
predominance imaging changes consistent with lower lobe
fibrosis (UIP pattern in most cases), relatively preserved
lung volumes contrasting with disproportionally impaired
gas exchange, severe exercise hypoxemia and poor prog-
nosis especially when pulmonary hypertension is present.
Despite a characteristic functional and radiological
profile it is still debatable whether CPFE represents
a distinct syndrome or a coincidence of pulmonary fi-
brosis with emphysema since no common pathogenetic
mechanisms have been drawn to encompass both dis-
ease entities.
Seminal observations regarding common pathogenetic
pathways between emphysema and lung fibrosis identi-
fied overexpression of key molecules including tumor
necrosis factor alpha (TNFa), platelet derived growth
factor (PDGF) and metalloproteinases (MMPs) 2, 7, 9 as
critical events leading to both alveolar and endothelial
cell destruction as well as thickening of the alveolar
septa depending on the lung zone [32,33]. Moreover, the
past few years, several studies implicated autoimmune
derangement and loss of immune tolerance in the patho-
genesis of both COPD [13,34-36] and lung fibrosis
[11,12], as indicated by a global numerical and functional
impairment of T regulatory cells and increased titers of cir-
culating anti-nuclear antibodies in patients with COPD
[14,34] and pulmonary fibrosis [1,12,37]. Further extending
the latter observations a close pathogenetic association be-
tween lung fibrosis and MPA, a type of small vessel vascu-
litis with renal and pulmonary involvement [38], has beenrecently demonstrated both in vivo and in vitro. More spe-
cifically, Tzelepis et al. [15] reported an increased incidence
of pulmonary fibrosis in patients with MPA while anti-
MPO antibodies have been demonstrated to induce oxi-
dative burst and fibroblast proliferation, thus, directly
contributing to lung fibrosis [16]. Further extending these
evidence, our group reported a case of a patient initially
diagnosed with CPFE that suddenly developed respiratory
and renal failure finally attributed to MPA with lung and
renal involvement [31].
On the basis of this finding,we conducted the first
study in the literature investigating autoimmunity profile
in a relatively large cohort of patients with CPFE. To this
end, we used a complete panel comprising of clinical,
serologic and histopathologic biomarkers and we com-
pared it to that observed in patients with IPF without
emphysema. Intriguingly both disease entities presented
with a distinct immunologic profile with patients with
CPFE characterized by an increased prevalence of positive
ANA and p-ANCA serum titers. Additionally, elevated
circulating anti-MPO concentrations were accompanied
by a relevant clinical phenotype compatible with either a
typical diagnosis of MPA with pulmonary involvement as
assessed by positive renal biopsy and diffuse alveolar al-
veolar hemorrhage leading to respiratory failure or a more
occult clinical phenotype encompassing asymptomatic
microscopic hematuria with normal renal function and
mild hypoxemia. Additional subgroup analysis of CPFE
patients with positive immunologic profile revealed that
there was no difference in terms of respiratory functional
status as well as radiological and histopathological pattern
between subjects with ANA+, ANCA+ or ANA-ANCA-
profile (Table 3). However, Kaplan-Meier survival analysis
revealed that the presence of autoimmunity may be linked
with a more favorable prognosis since patients with CPFE
and positive ANA profile exhibited a statistically signifi-
cant improved survival compared to those with negative
profile (median survival of 51 vs. 38 months, p = 0.052,
respectively). The latter observation is line with previous
reports showing that signs and serological evidence of
autoimmune disease may identify a group of patients with
NSIP exhibiting improved survival [39,40].
Investigating beyond this observation, representative
lung biopsy specimens from CPFE patients, with and
without positive serum immunologic profile, were im-
munostained with CD20, a marker of B cell presence. In-
triguingly, CD20+ B cells forming lymphoid follicles
were found within the fibrotic interstitium in areas adja-
cent to fibroblastic foci in CPFE patients with positive
serum ANA and p-ANCA profile whereas CD20+ cells
were almost absent in biopsy samples from patients with
CPFE and negative ANA profile as well as in control lung
samples. In addition, an almost linear positive correlation
between the number of CD20+ cells/mm2 of lung tissue
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onstrated (Figure 1b) evidence that further supports the
premise that serological and histopathologocal auto-
immune markers may be used as reliable disease prognos-
ticators. Nonetheless, it is worth noting that this is a
retrospective study enrolling patients under different treat-
ment arms and therefore a close association between posi-
tive autoimmune markers and disease survival cannot be
safely drawn. Further, prospective larger and well designed
studies using highly defined patients are sorely needed to
prove such hypothesis.
The presence of B cells, immediately adjacent to fibro-
blastic foci in CPFE patients with positive immunologic
profile, gives credence to the view that in certain cases
development of both fibrosis and emphysema may be as-
sociated with massive B cell infiltration that migrate into
the lung and are directed at infectious or apoptotic ma-
terial derived from repetitive injurious stimuli including
smoking and/or viruses. B cell follicular structures then
arise and give birth to germinal centers enabling B cell
isotype switching and antibody production. While on-
going smoking exposure, chronic lung inflammation and
lung injury proceed circulating neutrophils via endogen-
ous signals such as, IL-1 and other inflammatory cyto-
kines become primed and express intracellular antigens,
such as MPO on their surfaces [41,42]. This process may
last for prolonged periods of time even after smoking
cessation and may ultimately lead to the unintended rec-
ognition of self-antigens by somatically hypermutated
antibodies including ANA and/or p-ANCA that were
originally targeted to non self-antigens. Circulating
MPO-ANCA antibodies then attach to the primed neu-
trophil membranes promoting their destruction and the
release of reactive oxygen species located within the
neutrophilic cytoplasmic domain. The latter results in an
uncontrolled oxidative burst within the pulmonary
interstitium that could promote alveolar epithelial and
endothelial cell apoptosis and trigger fibroblast prolifera-
tion, as it has been clearly demonstrated with MPO-
induced advanced oxidation protein products from pa-
tients with MPA [16]. Additionally direct cytotoxicity of
MPO-ANCA antibodies in endothelial and epithelial
cells as well as fibrogenicity in resident lung fibroblasts
has also been proposed [16,41,42]. Moreover, the afore-
mentioned secondary protease-antiprotease imbalance
derived from neutrophil degranulation may explain focal
alveolar epithelial and endothelial cell destruction lead-
ing to emphysema [36].
Finally, the presence of a distinct histopathologic fea-
ture (CD20+ lymphoid follicles) that closely correlates
with serum immunologic profile and clearly differenti-
ates patients with CPFE into different groups (Table 3),
with distinct prognostic patterns (Figure 1a), is of major
importance since it may identify a specific subgroup ofCPFE patients with an asymptomatic ongoing autoimmune
process that may benefit from targeted immunomodulatory
or immunosuppressive therapeutic approaches. To this
end, CPFE patients exhibiting elevated titers of p-ANCA
without positive renal biopsy (n = 4) but accompanied by
an insidious clinical phenotype resembling to systemic vas-
culitis, with mild hypoxemia and asymptomatic micro-
scopic hematuria and normal renal function and 24-hour
urine protein levels were switched from pirfenidone treat-
ment to low doses of corticosteroids, azathioprine and
NAC. Due to the presence of relatively mild renal and pul-
monary involvement, we decided to apply a more conser-
vative therapeutic regimen and closely monitor renal and
lung function rather than implementing an aggressive
treatment approach with pulses of cyclophosphamide and
methylprednisolone or anti-CD20 biological agents.
Given their significant side-effects the application of the
aforementioned therapeutic agents could be limited for
more aggressive types of disease or otherwise in the
context of large randomized control trials in selective
groups of CPFE patients. Preliminary follow-up data
seems promising since all patients (n = 4) exhibited satis-
factory treatment response as assessed by both clinical
and functional stabilization (Table 4) as well as improved
survival.
Despite relative enthusiasm arising from the above data
our study exhibited a number of limitations that should be
addressed cautiously before rigid conclusions can be
drawn. Firstly and most importantly, this is a retrospective
study presenting with its original caveats and therefore it
is hard to delineate a temporal relationship between pres-
ence of auto-antibodies and specific clinical, radiological
and histopathological phenotypes. Secondly, based on the
study design it is impossible to prove a causal-effect rela-
tionship between circulating auto-antibodies and B cells
infiltration with alveolar epithelial and endothelial cell de-
struction leading to both lung fibrosis and emphysema.
Our results are more suggestive of the incidence of auto-
immune markers in patients with CPFE rather than
supportive of a specific pathogenetic linkage. Whether
CD20+ lymphoid follicular areas within the fibrotic lung
represent a causal event or a compensatory protective
response against fibrogenesis constitutes the subject of on-
going in vitro and experimental studies. Thirdly and most
importantly patients with CPFE exhibiting only ANA posi-
tivity could simply reflect false-positivity – and not convey
any autoimmune etiology. Finally, it is important to under-
line the fact that there is a significant background preva-
lence of ANA positivity in similar groups of otherwise
healthy individuals and therefore the presence or absence
of autoimmunity should not be based solely on non-
specific serologic markers [43]. In line with the aforemen-
tioned observations ANA positivity may simply reflect loss
of immune tolerance and not a flare of autoimmunity. A
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be administered in order to rigidly define the diagnosis of
autoimmune disease.Conclusions
Collectively this is the first study in the literature reporting
an increased incidence of non-specific as well as highly
specific autoantibodies for systemic vasculitis with renal
and pulmonary involvement namely MPA in patients with
CPFE compared to patients with IPF without emphysema.
Most intriguingly more than half of these patients
presented with normal renal function supporting the no-
tion that an occult autoimmune disorder with multi-organ
manifestations may reside insidiously under the diagnostic
“cover” of interstitial lung fibrosis and emphysema. Auto-
immunity involvement was further verified by intriguing
histopathologic data revealing lymphocytic infiltrates of
CD20+ B cells adjacent to areas of fibroblastic foci within
the fibrotic lung. In addition presence of autoimmunity
was strongly associated with favorable prognosis identify-
ing group of patients with distinct survival patterns. CPFE
occurring in the context of MPA may provide a common
pathogenetic mechanism for both emphysema and pul-
monary fibrosis. Detailed investigation of serum immuno-
logic profile and histopathology assessment using a panel
of markers of autoimmune activity, may help us to timely
identify a group of patients with unclassified autoimmune
disorders which may benefit from targeted immunosup-
pressive therapeutic interventions including anti-CD20
monoclonal antibody. In view of the current disappointing
survival data arising from large prospective placebo-
controlled clinical trials, the latter evidence is of vital im-
portance. Further well designed prospective controlled
studies are sorely needed to prove this premise.
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